16 research outputs found

    Molecular diagnosis reveals genetic heterogeneity for the overlapping MKKS and BBS phenotypes

    Get PDF
    Hydrometrocolpos and polydactyly diagnosed in the prenatal period or early childhood may raise diagnostic dilemmas especially in distinguishing McKusick-Kaufman syndrome (MKKS) and the Bardet-Biedl syndrome (BBS). These two conditions can initially overlap. With time, the additional features of BBS appearing in childhood, such as retinitis pigmentosa, obesity, learning disabilities and progressive renal dysfunction allow clear differentiation between BBS and MKKS. Genotype overlap also exists, as mutations in the MKKS-BBS6 gene are found in both syndromes. We report 7 patients diagnosed in the neonatal period with hydrometrocolpos and polydactyly who carry mutations in various BBS genes (BBS6, BBS2, BBS10, BBS8 and BBS12), stressing the importance of wide BBS genotyping in patients with this clinical association for diagnosis, prognosis and genetic counselling

    Human fetus and the civil state

    No full text

    Infection par le SARS-CoV-2 chez les femmes enceintes. Actualisation de l’état des connaissances et de la proposition de prise en charge. CNGOF

    No full text
    International audienceObjectives: The coronavirus SARS-CoV-2 identified late 2019 in China had spread across all continents. In the majority of cases, patients have mild symptoms (fever, cough, myalgia, headache, some digestive disorders) or are asymptomatic, however it can cause serious lung diseases and lead to death. On September 2020, over 28 million people have been infected with over 920,000 deaths.Methods: In view of the evolution of the epidemic the French National College of Obstetricians and Gynecologists has decided to update the recommendations previously issued. To do this, the same group of experts was called upon to carry out a review of the literature and take into account the opinions of the General Directorate of Health (DGS), the "Haute Autorité de Santé" (HAS) and the "Haut Conseil de santé Publique" (HCSP).Results: The data on consequences during pregnancy have accumulated. The symptoms in pregnant women appear to be similar to those of the general population, but an increased risk of respiratory distress exists in pregnant women especially in the third trimester. A case of intrauterine maternal-fetal transmission has been clearly identified. Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described.Conclusion: In light of the new data, we propose updated recommendations. These proposals may continue to evolve in view of the pandemic and of advances in studies in pregnant women.ObjectifsLe coronavirus SARS-CoV-2 mis en évidence en fin d’année 2019 en Chine a atteint tous les continents, avec plus de 28 millions de cas déclarés dont plus de 920 000 décès au 17/9/2020. Le plus souvent à l’origine d’un syndrome infectieux bénin, associant à différents degrés des symptômes (fièvre, toux, myalgies, céphalées et éventuels troubles digestifs), voire totalement asymptomatique, le SARS-CoV-2 peut être à l’origine de pathologies pulmonaires graves et parfois de décès.MéthodeAu vu de l’évolution de l’épidémie, le Collège national des gynécologues obstétriciens français a décidé de mettre à jours les avis émis précédemment. Pour cela, le même groupe d’experts, a été sollicité avec réalisation d’une revue de la littérature et prise en compte des avis de la Direction Générale de la Santé, la Haute Autorité de Santé, du Haut Conseil de Santé Publique.RésultatsLes données pendant la grossesse sont plus nombreuses et plus précises. Les données publiées semblent montrer que les symptômes chez les femmes enceintes sont les mêmes que ceux de la population générale et qu’un sur risque existe chez la femme enceinte particulièrement au troisième trimestre. Un cas de transmission materno-fœtale intra utérine a été formellement identifié. Une prématurité induite et des cas de détresses respiratoires chez les nouveau-nés de mères infectées ont été décrits.ConclusionÀ la lumière des nouvelles données, nous proposons une actualisation des recommandations de prise en charge. Ces propositions peuvent encore évoluer avec l’avancée de la pandémie et de potentielles nouvelles connaissances chez la femme enceinte

    Clinical research in implant dentistry: study design, reporting and outcome measurements: consensus report of Working Group 2 of the VIII European Workshop on Periodontology.

    No full text
    AIMS: The objective of this working group was to assess and make specific recommendations to improve the quality of reporting of clinical research in implant dentistry and discuss ways to reach a consensus on choice of outcomes. MATERIAL AND METHODS: Discussions were informed by three systematic reviews on quality of reporting of observational studies (case series, case-control and cohort) and experimental research (randomized clinical trials). An additional systematic review provided information on choice of outcomes and analytical methods. In addition, an open survey among all workshop participants was utilized to capture a consensus view on the limits of currently used survival and success-based outcomes as well as to identify domains that need to be captured by future outcome systems. RESULTS: The Workshop attempted to clarify the characteristics and the value in dental implant research of different study designs. In most areas, measurable quality improvements over time were identified. The Workshop recognized important aspects that require continued attention by clinical researchers, funding agencies and peer reviewers to decrease potential bias. With regard to choice of outcomes, the limitations of currently used systems were recognized. Three broad outcome domains that need to be captured by future research were identified: (i) patient reported outcome measures, (ii) peri-implant tissue health and (iii) performance of implant supported restorations. Peri-implant tissue health can be measured by marginal bone level changes and soft tissue inflammation and can be incorporated in time to event analyses. CONCLUSIONS: The Workshop recommended that collaboration between clinicians and epidemiologists/clinical trials specialists should be encouraged. Aspects of design aimed at limitation of potential bias should receive attention by clinical researchers, funding agencies and journal editors. Adherence to appropriate reporting guidelines such as STROBE and CONSORT are necessary standards. Research on outcome measure domains is an area of top priority and should urgently inform a proper process leading to a consensus on outcome measures in dental implant research

    Supplementary Material for: Evaluation of the Utility of in utero Treatment of Twin Anemia-Polycythemia Sequence

    No full text
    <b><i>Objective:</i></b> The aim of this study is to evaluate the interest in the in utero treatment of twin anemia-polycythemia sequence (TAPS). <b><i>Methods:</i></b> The obstetrical and neonatal data on all cases of TAPS followed up in our institution between 2006 and 2013 were reviewed. Statistical analyses were conducted using Bayesian methods. <b><i>Results:</i></b> Twenty cases of TAPS were included. Laser therapy or intrauterine transfusion (IUT) was performed on the donor twin in 9 cases. Eleven cases were included in the ‘nontreated' group (managed expectantly or diagnosed at birth). The gestational age at diagnosis was lower in the group with treated TAPS [difference (diff) = -22.20 days (-57.13, 14.28), probability (Pr) (diff >0) = 10.6%]. The rate of preterm premature rupture of membranes was higher in the group with treated TAPS [diff = 22.5% (-14, 57), Pr (diff >0) = 89%], but overall mortality was similar. The interval between diagnosis and delivery was longer [diff = 44.37 days (9.41, 77.90), Pr (diff >0) = 99.2%], the TAPS resolution rate was higher [diff = 49.9% (12, 81), Pr (diff >0) = 99.4%], and the neonatal transfusion rate was lower [diff = -30.5% (-60, 0), Pr (diff >0) = 2.6%] in the treated group. <b><i>Conclusion:</i></b> In utero treatment for TAPS is associated with a higher resolution rate of TAPS and a longer time between diagnosis and birth, but overall mortality is the same as with expectant management

    A multicenter randomized controlled trial using a novel collagen membrane for guided bone regeneration at dehisced single implant sites: Outcome at prosthetic delivery and at 1‐year follow‐up

    No full text
    ObjectivesTo compare clinical performance of a novel resorbable nonâ crossâ linked collagen membrane (CXP) with a reference membrane (nonâ crossâ linked resorbable membrane; BG) for simultaneous implant placement and guided bone regeneration (GBR) at dehisced single implant sites.Materials and methodsPreliminary data from this randomized controlled trial were reported previously; this is the 12â month report. The primary outcome measure was defected height at 6 months postâ GBR. Secondary outcomes included implant cumulative survival rate (CSR) and success rate since placement; bone level changes, pink esthetic score (PES), and patient satisfaction since definitive prosthesis delivery; patient quality of life since pretreatment; and the 1â year bleeding index. Nonâ parametric statistical analyses were performed.ResultsAmong patients, 24 were treated with CXP and 25 with BG. The 1â year implant CSR and success rate were 100% (n = 42). Bone level change between definitive prosthetic delivery and 1 year was not significantly different between the CXP and BG groups (BG + 0.42 mm, CXP + 0.01 mm). The PES increased from 7.55 to 8.10 for the CXP group and from 6.48 to 7.48 for the BG group; 1â year bleeding indices were 0 (16 CXP, 18 BG) and 1 (4 CXP, 2 BG). Patient quality of life changed from an OHIPâ 14 score of 6.5 at pretreatment to 1.9 at 1 year. Overall satisfaction (visual analogue score) with function and esthetics was 9.9 and 9.7, respectively. Interâ group differences were not significant for assessed outcomes. No deviceâ related adverse events were reported.ConclusionsThe use of CXP and BG for simultaneous implant placement and GBR at dehisced implant sites similarly reduced defect height and improved secondary measures, indicating nonâ inferiority.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149491/1/clr13426.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149491/2/clr13426_am.pd
    corecore